Find your ideal API manufacturing partner in high-growth markets globally List available now!

Ferriprox Patent Expiration

Ferriprox is a drug owned by Chiesi Usa Inc. It is protected by 8 US drug patents filed from 2015 to 2023. Out of these, 7 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 25, 2038. Details of Ferriprox's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10780055 Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(13 years from now)

Active
US11723874 Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(13 years from now)

Active
US11357731 Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(13 years from now)

Active
US11458103 Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(13 years from now)

Active
US10940116 Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(13 years from now)

Active
US10940115 Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(13 years from now)

Active
US8703156 Liquid formulation for deferiprone with palatable taste
Oct, 2029

(4 years from now)

Active
US7049328 Use for deferiprone
Jun, 2021

(3 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ferriprox's patents.

Given below is the list of recent legal activities going on the following patents of Ferriprox.

Activity Date Patent Number
Patent litigations
Patent Issue Date Used in PTA Calculation 15 Aug, 2023 US11723874
Recordation of Patent Grant Mailed 15 Aug, 2023 US11723874
Electronic Review 15 Aug, 2023 US11723874
Email Notification 15 Aug, 2023 US11723874
Patent eGrant Notification 15 Aug, 2023 US11723874
Recordation of Patent eGrant 15 Aug, 2023 US11723874
Mail Patent eGrant Notification 15 Aug, 2023 US11723874
Electronic Review 27 Jul, 2023 US11723874
Email Notification 27 Jul, 2023 US11723874
Issue Notification Mailed 26 Jul, 2023 US11723874


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Ferriprox and ongoing litigations to help you estimate the early arrival of Ferriprox generic.

Ferriprox's Litigations

Ferriprox been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 16, 2017, against patent number US7049328. The petitioner Taro, challenged the validity of this patent, with ApoPharma Inc. as the respondent. Click below to track the latest information on how companies are challenging Ferriprox's patents.

Last updated on December 17, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7049328 May, 2017 Terminated-Settled
(07 Aug, 2018)
ApoPharma Inc. Taro


FDA has granted some exclusivities to Ferriprox. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Ferriprox, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Ferriprox.

Exclusivity Information

Ferriprox holds 9 exclusivities out of which 4 have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Ferriprox's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 14, 2016
Orphan Drug Exclusivity(ODE) Oct 14, 2018
Orphan Drug Exclusivity(ODE-16) Oct 14, 2018
New Indication(I-859) Apr 30, 2024
Orphan Drug Exclusivity(ODE-417) Apr 30, 2028
Orphan Drug Exclusivity(ODE-418) Apr 30, 2028
Orphan Drug Exclusivity(ODE-419) Apr 30, 2028
Orphan Drug Exclusivity(ODE-420) Apr 30, 2028
Orphan Drug Exclusivity(ODE-421) Apr 30, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Ferriprox is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ferriprox's family patents as well as insights into ongoing legal events on those patents.

Ferriprox's Family Patents

Ferriprox has patent protection in a total of 29 countries. It's US patent count contributes only to 21.2% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Ferriprox.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Ferriprox's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 25, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Ferriprox Generic API suppliers:

Deferiprone is the generic name for the brand Ferriprox. 2 different companies have already filed for the generic of Ferriprox, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ferriprox's generic

How can I launch a generic of Ferriprox before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Ferriprox's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Ferriprox's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Ferriprox -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
500 mg 29 Jan, 2016 1 08 Feb, 2019 28 Jun, 2021 Eligible





About Ferriprox

Ferriprox is a drug owned by Chiesi Usa Inc. It is used for managing transfusional iron overload. Ferriprox uses Deferiprone as an active ingredient. Ferriprox was launched by Chiesi in 2020.

Approval Date:

Ferriprox was approved by FDA for market use on 19 May, 2020.

Active Ingredient:

Ferriprox uses Deferiprone as the active ingredient. Check out other Drugs and Companies using Deferiprone ingredient

Treatment:

Ferriprox is used for managing transfusional iron overload.

Dosage:

Ferriprox is available in the following dosage forms - solution form for oral use, tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
1GM TABLET Prescription ORAL
80MG/ML SOLUTION Discontinued ORAL
100MG/ML SOLUTION Prescription ORAL
500MG TABLET Prescription ORAL